Boehringer Ingelheim and Medivir entered into licensing agreement for Medivir’s antiviral drug, MIV-310 for treating multi-drug resistant HIV-1. The deal could be worth up to US$137 M to Medivir in addition to double-digit royalties on product sales. Boehringer will gain marketing rights across the world from Medivir except for Sweden, Denmark, Finland, Norway and Iceland.